Breast Cancer Therapeutics
Clinical research focuses on recurrent and metastatic HER2-negative breast cancer, with interest in treatment options for patients requiring first-line systemic therapy.
- HER2-negative breast cancer
- Recurrent disease
- Metastatic disease
The sponsor’s current research activity is centered on oncology care in advanced breast cancer settings.
Taxane-based Chemotherapy
Its trial portfolio includes interest in paclitaxel as a treatment option within taxane chemotherapy for solid tumor management.
- Paclitaxel
- Taxane chemotherapy
- Systemic anticancer therapy
This reflects a therapeutic focus on established cytotoxic agents used in breast cancer treatment.
Oral Oncology Treatments
Research interest extends to oral paclitaxel, highlighting development activity in orally administered oncology medicines for patients with advanced breast cancer.
- Oral paclitaxel
- Oral anticancer therapy
- Convenient treatment administration
The sponsor is engaged in evaluating treatment options that may broaden the use of paclitaxel in clinical oncology.
Comparative Cancer Treatment Evaluation
Clinical interest includes the assessment of efficacy and safety in comparison with established intravenous therapy for breast cancer.
- Efficacy assessment
- Safety evaluation
- Intravenous paclitaxel
Current activity is concentrated in a single active study site in South Korea, within the sponsor’s oncology development program.
